More on ALKS
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $46.71 |
|
|||
| Open | $46.51 | ||||
| 52 Wk High | $80.71 | ||||
| 52 Wk Low | $27.14 | ||||
| Day High | $46.53 | ||||
| Day Low | $43.27 | ||||
| P/E | 333.77 | ||||
| EPS | $0.13 | ||||
| Volume | 6,739,526 | ||||
- Form 8-K Alkermes plc. For: Sep 14
- Alkermes adds Anne Whitaker to its board of directors
- Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
- Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
- Mizuho Reiterates Outperform Rating on Alkermes (ALKS)
- Alkermes narcolepsy drug data published in The Lancet Neurology
- The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
- Form 4 Alkermes plc. For: Aug 17 Filed by: Nichols Christian Todd
- Form 144 Alkermes plc. Filed by: Nichols Christian Todd
- Form 4 Alkermes plc. For: Aug 03 Filed by: snyderman nancy lynn MD
Entities mentioned with ALKS
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
